🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ICYMI: Drew Titmarsh, CEO of Dynomics discusses the lack of innovative therapies to treat #heartdisease, and how it uses engineered cardiac organoids to develop precision therapies to address the root causes of heart failure. bioverge.com/blog/the-biove…

Bioverge Monthly Sept. '23 Our newest iteration of The Bioverge Monthly newsletter starts from the top (e.g. the big picture) and will track several key macroeconomic metrics, before we drill down into the biotech markets, both public and private. open.substack.com/pub/biovergeve…

Nice summary from No Patient Left Behind on what it takes to develop and commercialize new medicines that collectively benefit us all.

We are proud to be selected by the Endpoints News editorial team as one of the most promising and ambitious #biotech startups! We’re grateful for the recognition of what we’ve built so far and where we are headed next: the clinic in 2024! endpts.com/the-endpoints-…

Exciting clinical results from our portfolio company Alto Neuroscience further validating their platform and approach to treating neuropsychiatric disorders!

On the latest pod, Nathan Hunkapiller, CEO of Curve Biosciences, discusses liquid biopsies, the company’s efforts to expand the use of these blood-based tests to improve the treatment of chronic diseases, and how it is enabling earlier intervention. bioverge.com/blog/the-biove…

On the latest pod, Faizzan Ahmad, CEO of Cure8bio, discusses the company’s growing portfolio of regenerative medicines, its hub-and-spoke business model designed to leverage resources and reduce risk, and its push toward curative therapies. Listen today: bioverge.com/blog/the-biove…

The Bioverge Monthly Newsletter November edition is out! Macro: "In the past three months, we've experienced a pronounced yield curve shift, specifically a bear steepening driven by long-term rate changes." And the first-ever CRISPR Drug approval! open.substack.com/pub/biovergeve…

Today we announced the successful close of an oversubscribed $45 million Series C Financing. Read more here: brnw.ch/21wEDXw

ICYMI: On the pod, Nathan Hunkapiller, CEO of Curve Biosciences, discusses liquid biopsies, the company’s efforts to expand the use of these blood-based tests to improve the treatment of #chronicdisease, and how it is enabling earlier intervention bioverge.com/blog/the-biove…

Thrilled to welcome Kiersten Stead DCVC Bio to the pod to discuss her firm’s approach to deep tech investing in biotech, her focus on platform technologies, and how to separate what’s real from what’s hype in AI. bioverge.com/blog/copy-copy…

The January edition of Bioverge Monthly is out! Discover more about the surge of optimism resulting from a dynamic M&A market and gain insights into the current trends in the private markets. open.substack.com/pub/biovergeve…

🔔 And just like that, Alto is trading on NYSE 🏛! We are thrilled to be taking this next step as a company and furthering our mission to redefine psychiatry via personalized and highly effective treatment options in #MentalHealth. $ANRO

Today Alto Neuroscience began trading on the NYSE 🏛 under the ticker $ANRO. I founded Alto out of the desire to give patients better treatment options than those that are currently available. Today we take one step closer to our goal of making #PrecisionPsychiatry a reality.